Novo Nordisk (BUL:NOV) - Cotización, noticias y análisis

Resumen de acción NOV

NOV fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	6/6
Financial Health	4/6
Dividends	3/6

Recompensas

Se prevé un crecimiento anual de los beneficios de 15.24%

Los beneficios aumentaron un 42.6% el año pasado

Análisis de riesgos

Acciones altamente ilíquidas

Venta significativa por parte de personas con información privilegiada en los últimos 3 meses

Competidores de Novo Nordisk A/S

Eli Lilly

NYSE:LLY

US$654.2b

Johnson & Johnson

NYSE:JNJ

US$356.4b

AstraZeneca

LSE:AZN

UK£169.7b

Sopharma AD

BUL:SFA

лв1.0b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Novo Nordisk
Historical stock prices
Current Share Price	kr.111.70
52 Week High	kr.112.14
52 Week Low	kr.86.78
Beta	0.20
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	121.65%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	NOV	BG Pharmaceuticals	Mercado BG
7D	0%	-1.3%	0.3%
1Y	n/a	4.4%	16.0%

Rentabilidad vs. Industria: Datos insuficientes para determinar los resultados de NOV en comparación con el sector BG Pharmaceuticals .

Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de NOV frente al mercado BG.

Volatilidad de los precios

Is NOV's price volatile compared to industry and market?
NOV volatility
NOV Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.1%
Market Average Movement	4.1%
10% most volatile stocks in BG Market	8.2%
10% least volatile stocks in BG Market	2.1%

Precio estable de las acciones: NOV no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de NOV en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1923	63,845	Lars Jorgensen	www.novonordisk.com

Novo Nordisk A/S, junto con sus filiales, se dedica a la investigación y desarrollo, fabricación y distribución de productos farmacéuticos en Europa, Oriente Medio, África, China continental, Hong Kong, Taiwán, Norteamérica e internacionalmente. Opera en dos segmentos, Diabetes y Obesidad, y Enfermedades Raras. El segmento de Diabetes y Obesidad ofrece productos para diabetes, obesidad, enfermedades cardiovasculares y otras áreas terapéuticas emergentes.

Resumen de fundamentos de Novo Nordisk A/S

¿Cómo se comparan los beneficios e ingresos de Novo Nordisk con su capitalización de mercado?
Estadísticas fundamentales de NOV
Capitalización bursátil	€517.90b
Beneficios(TTM)	€11.21b
Ingresos (TTM)	€31.13b

46.2x

Ratio precio-beneficio (PE)

16.6x

Ratio precio-ventas (PS)

¿Está NOV sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de NOV
Ingresos	kr.232.26b
Coste de los ingresos	kr.35.77b
Beneficio bruto	kr.196.50b
Otros gastos	kr.112.81b
Beneficios	kr.83.68b

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

May 02, 2024

Beneficios por acción (BPA)	18.76
Margen bruto	84.60%
Margen de beneficio neto	36.03%
Ratio deuda/patrimonio	20.0%

¿Cómo se ha desempeñado NOV a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

1.1%

Rentabilidad actual por dividendo

50%

Ratio de pagos

Resumen de acción NOV

Recompensas

Análisis de riesgos

Competidores de Novo Nordisk A/S

NYSE:LLY

US$654.2b

NYSE:JNJ

US$356.4b

LSE:AZN

UK£169.7b

BUL:SFA

лв1.0b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

President recently sold €19m worth of stock

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Recent updates

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

President recently sold €19m worth of stock

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Executive VP of Product Supply recently sold €1.8m worth of stock

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

New minor risk - Shareholder dilution

New minor risk - Dividend sustainability

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares

Novo Nordisk A/S Announces Headline Results from OASIS 1

Novo Nordisk A/S to Report Fiscal Year 2023 Results on Jan 31, 2024

Heartseed and Novo Nordisk A/S Announces First Patient Dosed in Clinical Study with HS-001 – A Cell Therapy Designed to Restore Heart Function in People with Advanced Heart Failure

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 28,000 million worth of its shares.

Novo Nordisk Announces FDA Approval of Label Update for Rybelsus® (Semaglutide) Allowing Use as a First-Line Option for Adults with Type 2 Diabetes

Investor sentiment improved over the past week

Novo Nordisk A/S to Report First Half, 2023 Results on Aug 10, 2023

Novo Nordisk Announces Headline Results from the ONWARDS 5 Phase 3A Trial with Once-Weekly Insulin Icodec in People with Type 2 Diabetes

Novo Nordisk A/S (CPSE:NOVO B) entered into a definitive agreement to acquire Forma Therapeutics Holdings, Inc. (NasdaqGM:FMTX) from RA Capital Management, L.P. and others for approximately $990 million

Novo Nordisk A/S (CPSE:NOVO B) entered into a definitive agreement to acquire Forma Therapeutics Holdings, Inc. (NasdaqGM:FMTX) from RA Capital Management, L.P. and others for approximately $990 million

Novo Nordisk A/S Successfully Completes Phase 2 Trial with Cagrisema in People with Type 2 Diabetes

Second quarter 2022 earnings released

Novo Nordisk A/S Revises Earnings Guidance for the Full Year of 2022

Novo Nordisk Achieves Primary Objectives of Onwards 3 and 4 Trials with Once-Weekly Insulin Icodec Demonstrating Superior Reduction in Hba1c Vs Insulin Degludec in Onwards 3

Novo Nordisk Achieves Primary Objectives of ONWARDS 1 and 6 Trials

Now 22% undervalued

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Novo Nordisk A/S

46.2x

16.6x

Beneficios e Ingresos

Dividendos

1.1%

50%